Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration.

Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, Lin CM, Mitra D, Zhu D, Thomas BB, Hikita ST, Pennington BO, Johnson LV, Clegg DO, Hinton DR, Humayun MS.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaao4097. doi: 10.1126/scitranslmed.aao4097.

PMID:
29618560
2.

LARGE SILICONE DROPLETS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN).

Avery RL, Castellarin AA, Dhoot DS, Pieramici DJ, Nasir MA, Steinle NC, Avery LP, Gordon GM.

Retin Cases Brief Rep. 2017 Mar 15. doi: 10.1097/ICB.0000000000000570. [Epub ahead of print]

PMID:
28301412
3.

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.

Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, Van Everen S, Le K, Hanley WD.

Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493.

4.

Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.

Dhoot DS, Avery RL.

Curr Diab Rep. 2016 Dec;16(12):122. Review.

PMID:
27766582
5.

TREATMENT OF VITREOMACULAR TRACTION WITH INTRAVITREAL PERFLUOROPROPANE (C3F8) INJECTION.

Steinle NC, Dhoot DS, Quezada Ruiz C, Castellarin AA, Pieramici DJ, See RF, Couvillion SC, Nasir MA, Avery RL.

Retina. 2017 Apr;37(4):643-650. doi: 10.1097/IAE.0000000000001237.

PMID:
27681001
6.
7.

Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.

Avery RL, Gordon GM.

JAMA Ophthalmol. 2016 Jan;134(1):21-9. doi: 10.1001/jamaophthalmol.2015.4070. Review.

PMID:
26513684
8.

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.

Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel.

JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.

PMID:
26512939
9.

A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study.

Eaton AM, Gordon GM, Konowal A, Allen A, Allen M, Sgarlata A, Gao G, Wafapoor H, Avery RL.

Eye (Lond). 2015 Oct;29(10):1383-91. doi: 10.1038/eye.2015.155. Epub 2015 Sep 11.

10.

Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.

Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL.

Retina. 2015 Jun;35(6):1144-50. doi: 10.1097/IAE.0000000000000544.

PMID:
25961122
11.

Identification of a Novel Mucin Gene HCG22 Associated With Steroid-Induced Ocular Hypertension.

Jeong S, Patel N, Edlund CK, Hartiala J, Hazelett DJ, Itakura T, Wu PC, Avery RL, Davis JL, Flynn HW, Lalwani G, Puliafito CA, Wafapoor H, Hijikata M, Keicho N, Gao X, Argüeso P, Allayee H, Coetzee GA, Pletcher MT, Conti DV, Schwartz SG, Eaton AM, Fini ME.

Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2737-48. doi: 10.1167/iovs.14-14803.

12.

Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study).

Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL.

Eye (Lond). 2015 Apr;29(4):534-41. doi: 10.1038/eye.2014.338. Epub 2015 Jan 30.

13.

Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy.

Zlotcavitch L, Flynn HW Jr, Avery RL, Rachitskaya A.

Clin Ophthalmol. 2015 Jan 6;9:69-71. doi: 10.2147/OPTH.S69466. eCollection 2015.

14.

Intravitreal injection technique and monitoring: updated guidelines of an expert panel.

Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, DʼAmico DJ, Dugel PU, Flynn HW Jr, Freund KB, Haller JA, Jumper JM, Liebmann JM, McCannel CA, Mieler WF, Ta CN, Williams GA.

Retina. 2014 Dec;34 Suppl 12:S1-S18. doi: 10.1097/IAE.0000000000000399.

PMID:
25489719
15.

Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection.

Quezada Ruiz C, Pieramici DJ, Nasir M, Rabena M, Avery RL.

Retin Cases Brief Rep. 2015 Spring;9(2):145-8. doi: 10.1097/ICB.0000000000000120.

PMID:
25462129
16.

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE.

Br J Ophthalmol. 2014 Dec;98(12):1636-41. doi: 10.1136/bjophthalmol-2014-305252. Epub 2014 Jul 7.

17.

Injection force comparison of the old and new dexamethasone implant insertion needles in porcine eyes and synthetic sclera.

Eaton AM, Gordon GM, Booth D, Wafapoor H, Avery RL.

Ophthalmic Surg Lasers Imaging Retina. 2014 May-Jun;45(3):232-8. doi: 10.3928/23258160-20140430-01. Epub 2014 May 12.

PMID:
24806429
18.

What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

Avery RL.

Br J Ophthalmol. 2014 Jun;98 Suppl 1:i7-10. doi: 10.1136/bjophthalmol-2013-303844. Epub 2013 Dec 10. Review.

19.

Assessment of novel guarded needle to increase patient comfort and decrease injection time during intravitreal injection.

Eaton AM, Gordon GM, Wafapoor H, Sgarlata A, Avery RL.

Ophthalmic Surg Lasers Imaging Retina. 2013 Nov 1;44(6):561-8. doi: 10.3928/23258160-20131105-06.

PMID:
24221463
20.

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.

Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group).

Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May 22.

21.

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.

Williams PD, Callanan D, Solley W, Avery RL, Pieramici DJ, Aaberg T.

Clin Ophthalmol. 2012;6:1519-25. doi: 10.2147/OPTH.S31010. Epub 2012 Sep 17.

22.

Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?

Avery RL.

J AAPOS. 2012 Feb;16(1):2-4. doi: 10.1016/j.jaapos.2011.11.002. Epub 2012 Jan 10. No abstract available.

PMID:
22237669
23.

Endophthalmitis in microincision vitrectomy: outcomes of gas-filled eyes.

Chiang A, Kaiser RS, Avery RL, Dugel PU, Eliott D, Shah SP, Heier J, Duker J, Hu AY, Schwartz SD, Scott IU, Pollack JS, Faia LJ, Williams GA.

Retina. 2011 Sep;31(8):1513-7. doi: 10.1097/IAE.0b013e3182209290.

PMID:
21878799
24.

Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.

Risard SM, Pieramici DJ, Rabena MD, Basefsky JC, Avery RL, Castellarin AA, Nasir MA, See RF, Couvillion SS.

Retina. 2011 Jun;31(6):1060-7. doi: 10.1097/IAE.0b013e3181fbce76.

PMID:
21283055
25.

The plague and macular degeneration.

Avery RL.

Ophthalmology. 2010 Dec;117(12):2442. doi: 10.1016/j.ophtha.2010.08.052. Epub 2010 Oct 8. No abstract available.

PMID:
20932580
26.

Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern.

Avery RL.

J AAPOS. 2009 Aug;13(4):329-31. doi: 10.1016/j.jaapos.2009.06.003. No abstract available.

PMID:
19683181
27.

Diagnostic and therapeutic challenges.

Murakami Y, Kusaka S, Oshima Y, Tano Y, Avery RL, Pieramici DJ, Arevalo JF.

Retina. 2008 Oct;28(9):1357-60. doi: 10.1097/IAE.0b013e318181b923. No abstract available.

PMID:
19430394
28.

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.

Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL.

Ophthalmology. 2008 Oct;115(10):e47-54. doi: 10.1016/j.ophtha.2008.06.021. Epub 2008 Aug 16.

PMID:
18708258
29.

Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.

Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, Buehler J, Chen Y, Yu B, Tinkham NH, Zabriskie NA, Zeng J, Luo L, Sun JK, Prakash M, Hamam RN, Tonna S, Constantine R, Ronquillo CC, Sadda S, Avery RL, Brand JM, London N, Anduze AL, King GL, Bernstein PS, Watkins S; Genetics of Diabetes and Diabetic Complication Study Group, Jorde LB, Li DY, Aiello LP, Pollak MR, Zhang K.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):6998-7003. doi: 10.1073/pnas.0800454105. Epub 2008 May 5.

30.

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.

Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG.

Br J Ophthalmol. 2008 Feb;92(2):213-6. Epub 2007 Oct 26.

PMID:
17965108
31.

New treatments for age-related macular degeneration.

Avery RL.

Lancet. 2007 Oct 27;370(9597):1479-80; author reply 1480. No abstract available.

PMID:
17964341
32.

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.

Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL.

Retina. 2007 Apr-May;27(4):419-25.

PMID:
17420692
33.

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.

Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP, Feener EP.

Nat Med. 2007 Feb;13(2):181-8. Epub 2007 Jan 28.

PMID:
17259996
34.

Identification of ganglion cell neurites in human subretinal and epiretinal membranes.

Lewis GP, Betts KE, Sethi CS, Charteris DG, Lesnik-Oberstein SY, Avery RL, Fisher SK.

Br J Ophthalmol. 2007 Sep;91(9):1234-8. Epub 2006 Nov 15.

35.

Ranibizumab: treatment in patients with neovascular age-related macular degeneration.

Pieramici DJ, Avery RL.

Expert Opin Biol Ther. 2006 Nov;6(11):1237-45. Review.

PMID:
17049020
36.

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A.

Ophthalmology. 2006 Oct;113(10):1695.e1-15.

PMID:
17011951
37.

Case of anterior uveitis after intravitreal injection of bevacizumab.

Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M.

Retina. 2006 Sep;26(7):841-2. No abstract available.

PMID:
16963867
38.

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

Avery RL.

Retina. 2006 Mar;26(3):352-4. No abstract available.

PMID:
16508438
39.

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A.

Retina. 2006 Mar;26(3):262-9.

PMID:
16508424
40.

Cryptic sexual conflict in gift-giving insects: chasing the chase-away.

Sakaluk SK, Avery RL, Weddle CB.

Am Nat. 2006 Jan;167(1):94-104. Epub 2005 Nov 7.

PMID:
16475102
41.

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.

Ophthalmology. 2006 Mar;113(3):363-372.e5. Epub 2006 Feb 3.

PMID:
16458968
42.

The efficacy of delayed oxygen therapy in the treatment of experimental retinal detachment.

Lewis GP, Talaga KC, Linberg KA, Avery RL, Fisher SK.

Am J Ophthalmol. 2004 Jun;137(6):1085-95.

PMID:
15183794
43.

Augmentation of filtering blebs with perfluoropropane gas bubble.

Luttrull JK, Avery RL.

Ophthalmology. 2000 Feb;107(2):223-4; author reply 225. No abstract available.

PMID:
10690810
44.

Initial experience with pneumatically stented baerveldt implant modified for pars plana insertion for complicated glaucoma.

Luttrull JK, Avery RL, Baerveldt G, Easley KA.

Ophthalmology. 2000 Jan;107(1):143-9; discussion 149-50.

PMID:
10647733
45.

Peripheral transscleral retinal diode laser for rubeosis iridis.

Luttrull JK, Avery RL.

Retina. 1998;18(4):389. No abstract available.

PMID:
9730191
46.

Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration.

Avery RL, Fekrat S, Hawkins BS, Bressler NM.

Retina. 1996;16(3):183-9.

PMID:
8789855
47.

Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE.

Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9.

48.

Pars plana implant and vitrectomy for treatment of neovascular glaucoma.

Luttrull JK, Avery RL.

Retina. 1995;15(5):379-87.

PMID:
8594629
49.

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al.

N Engl J Med. 1994 Dec 1;331(22):1480-7.

50.

Suture abscesses after penetrating keratoplasty.

Leahey AB, Avery RL, Gottsch JD, Mallette RA, Stark WJ.

Cornea. 1993 Nov;12(6):489-92.

PMID:
8261779

Supplemental Content

Loading ...
Support Center